PCVX.NASDAQVaxcyte, INC
10-Q: Vaxcyte Reports Second Quarter 2024 Financial Results, Provides Update on Vaccine Programs
Sentiment:
Quarterly Report
Vaxcyte, a clinical-stage vaccine company, reported a net loss of $128.7 million for the second quarter of 2024, while advancing its pipeline of vaccine candidates.
Delay expectedThe cumulative impact of the time required to make adjustments to the manufacturing processes led to a delay of the drug substance manufacturing campaign due to scheduling conflicts and capacity constraints at Lonza.
Capital raiseThe company states that it will continue to require additional capital to develop and commercialize its vaccine candidates and fund operations for the foreseeable future.The company expects to finance its cash needs through public or private equity or debt financings, third-party funding, and strategic alliances.
Summary
- Vaxcyte reported a net loss of $128.7 million for the three months ended June 30, 2024, and a net loss of $223.7 million for the six months ended June 30, 2024.
- Research and development expenses were $131.5 million for the quarter and $226.1 million for the six months ended June 30, 2024, driven by manufacturing activities and clinical trial costs.
- The company's cash, cash equivalents, and investments totaled $1.85 billion as of June 30, 2024.
- Vaxcyte completed enrollment in the Phase 2 clinical study evaluating VAX-24 in healthy infants and expects topline data by the end of the first quarter of 2025.
- The company also completed enrollment in the Phase 1/2 clinical study evaluating VAX-31 in healthy adults aged 50 and older, with topline data expected in September 2024.
- Vaxcyte continues to advance its other vaccine programs, including VAX-A1, VAX-PG, and VAX-GI.
Sentiment
Score: 6
Explanation: The document presents a mixed picture. While the company is making progress in its clinical trials and has a strong cash position, it is also incurring significant losses and faces numerous risks. The sentiment is cautiously optimistic, reflecting the inherent uncertainties in drug development.
Positives
- Vaxcyte has a strong cash position of $1.85 billion, providing financial flexibility for ongoing development programs.
- The company has completed enrollment in key clinical trials for VAX-24 and VAX-31, moving closer to potential data readouts.
- Vaxcyte is advancing multiple vaccine programs, demonstrating a commitment to expanding its pipeline.
- The company has a commercial manufacturing agreement with Lonza, securing future manufacturing capacity.
Negatives
- Vaxcyte continues to incur significant net losses, with a net loss of $128.7 million for the second quarter of 2024.
- Research and development expenses are substantial, reflecting the high cost of clinical development.
- The company is reliant on third-party manufacturers, which introduces supply chain risks.
- The company has no products approved for sale and has not generated any revenue from product sales.
Risks
- The company is in the clinical or preclinical stages of vaccine development and has a limited operating history.
- Vaxcyte will require substantial additional funding to finance its operations.
- The company's approach to vaccine development is based on novel technologies that are unproven.
- The company's vaccine candidates may fail in development or suffer delays.
- The FDA may disagree with the company's regulatory plan, and the company may fail to obtain regulatory approval.
- The company is highly dependent on the success of its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31.
- The company's primary competitors have significantly greater resources and experience.
- The company relies on third-party manufacturing and supply partners.
- The FDA regulatory approval process is lengthy and time-consuming.
- The company may not be successful in its efforts to use its cell-free protein synthesis platform to expand its pipeline of vaccine candidates.
Future Outlook
Vaxcyte expects to announce topline data from the Phase 2 study of VAX-24 in infants by the end of the first quarter of 2025 and topline data from the Phase 1/2 study of VAX-31 in adults in September 2024. The company will then determine whether to advance VAX-24 or VAX-31 to an adult Phase 3 program.
Management Comments
- The company believes there is agreement with the FDA on the clinical design of a potential adult Phase 3 program for VAX-24.
- The company expects to seek additional CMC-focused input from the FDA as it prepares for and potentially conducts its VAX-24 adult Phase 3 program.
Industry Context
Vaxcyte is operating in the competitive vaccine market, where major pharmaceutical companies like Pfizer, Merck, GSK, and Sanofi are also developing pneumococcal vaccines. The company's focus on broad-spectrum conjugate vaccines and novel protein vaccines positions it to potentially address unmet needs in the market.
Comparison to Industry Standards
- Vaxcyte's VAX-24 is designed to improve upon the standard-of-care PCVs for both children and adults by covering the serotypes that are responsible for a significant portion of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice, this is similar to the approach taken by Pfizer with PCV20 and Merck with PCV15 and PCV21.
- VAX-31 is designed to expand the breadth of coverage to 31 strains, inclusive of the 24 strains in VAX-24, without compromising immunogenicity due to carrier suppression, and to cover more than 95% of IPD circulating in the U.S. adult population, this is a similar approach to GSK's 30-plus valent pneumococcal candidate vaccine in preclinical development.
- Vaxcyte's use of cell-free protein synthesis platform is a novel approach compared to traditional cell-based approaches used by competitors, which may accelerate the development and manufacturing of high-fidelity vaccines.
- The company's reliance on third-party manufacturers, including Lonza, is a common practice in the biopharmaceutical industry, but it introduces supply chain risks that need to be managed.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | John Furey | 2024-07-01 | Appointed to the Board of Directors |
Stakeholder Impact
- Shareholders: The company's financial performance and progress in clinical trials will impact shareholder value.
- Employees: The company's growth and development activities will affect employee opportunities and job security.
- Customers: The company's vaccine candidates, if approved, will provide new options for preventing bacterial diseases.
- Suppliers: The company's reliance on third-party manufacturers will impact their business and operations.
- Creditors: The company's financial performance and ability to raise capital will affect its creditworthiness.
Next Steps
- Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 primary three-dose immunization series for VAX-24 by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
- Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 1/2 study for VAX-31 in September 2024.
- The company expects to determine whether to advance VAX-24 or VAX-31 to an adult Phase 3 program following the topline data from the VAX-31 adult Phase 1/2 study.
Key Dates
| Date | Description |
|---|---|
| 2013-11-27 | Vaxcyte, Inc. was incorporated in the state of Delaware as SutroVax, Inc. |
| 2015-10-12 | Vaxcyte entered into an amended and restated license agreement with Sutro Biopharma. |
| 2020-05-15 | SutroVax, Inc. changed its name to Vaxcyte, Inc. |
| 2020-06-11 | The 2020 Equity Incentive Plan became effective. |
| 2021-01-01 | Vaxcyte entered into a lease agreement for its current corporate headquarters facility. |
| 2021-04-01 | Vaxcyte received its first grant from the NIH. |
| 2022-12-01 | Vaxcyte entered into an option grant agreement with Sutro Biopharma. |
| 2023-02-27 | Vaxcyte and Jefferies entered into an amendment to the Original ATM Sales Agreement. |
| 2023-03-01 | Vaxcyte entered into a non-exclusive development and manufacturing services agreement with Lonza. |
| 2023-03-22 | Vaxcyte entered into a non-exclusive development and manufacturing services agreement with Lonza. |
| 2023-04-01 | Vaxcyte completed an underwritten public offering of common stock and pre-funded warrants. |
| 2023-06-01 | Vaxcyte received another grant from the NIH. |
| 2023-09-01 | Vaxcyte entered into an assignment and assumption of lease agreement. |
| 2023-09-28 | Vaxcyte and Sutro Biopharma mutually agreed in writing upon the Form Definitive Agreement. |
| 2023-10-02 | Vaxcyte paid the $5.0 million accrued commitment to Sutro Biopharma. |
| 2023-10-13 | Vaxcyte GmbH entered into a pre-commercial services and commercial manufacturing supply agreement with Lonza. |
| 2023-10-25 | Vaxcyte formed Vaxcyte Switzerland GmbH. |
| 2023-10-31 | Vaxcyte amended the 2022 Lonza DMSA. |
| 2023-11-21 | Vaxcyte exercised the Option by submitting written notice thereof to Sutro Biopharma and concurrently paid Sutro Biopharma $50.0 million in cash. |
| 2024-01-01 | The number of shares of common stock available under the 2020 Plan increased by 4,768,241 shares. |
| 2024-01-31 | Vaxcyte completed an underwritten public offering of common stock and pre-funded warrants. |
| 2024-05-13 | Vaxcyte paid the second and final installment of $25.0 million in cash for the Option exercise. |
| 2024-06-30 | End of the reporting period. |
| 2024-07-01 | Grant Pickering's 10b5-1 Plan effective date. |
| 2024-07-01 | Vaxcyte received a five-year, $9.5 million grant from the NIAID. |
| 2024-07-01 | Vaxcyte appointed John Furey to its Board of Directors. |
| 2024-07-31 | Vaxcyte sold a total of 881,307 shares of its common stock under the Amended ATM Sales Agreement. |
| 2024-08-05 | Vaxcyte sold a total of 881,307 shares of its common stock under the Amended ATM Sales Agreement. |
| 2024-08-06 | Date of the report. |
| 2024-10-01 | Mikhail Eydelman's 10b5-1 Plan effective date. |
| 2024-10-01 | Grant Pickering's 10b5-1 Plan effective date. |
| 2024-10-18 | Andrew Guggenhime's 10b5-1 Plan effective date. |
| 2024-09-16 | Teri Loxam's 10b5-1 Plan effective date. |
Keywords
vaccine, clinical trials, pneumococcal, VAX-24, VAX-31, biopharmaceutical, research and development, manufacturing, FDA, immunogenicity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.